Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover extension study of open-label iptacopan in adults with primary IgA nephropathy
jRCT2021210041Recruiting
- Sponsor
- Novartis
- Start
- Nov 2021
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of Iptacopan in IgA nephropathy (IgAN), sponsored by Novartis. Primary endpoint: Safety and tolerability of iptacopan. Started Nov 2021; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2021210041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210041.